Clinical Trials match your criteria
-
ELACESTRANT vs. SOC FOR PATIENTS WITH ER+/HER2- FOLLOWING CDK4/6 INHIBITOR THERAPY
ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL (EMERALD)
-
The PROOF Trial_QBGJ398-301
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial
-
Ribociclib+Endocrine Therapy as Ad Tx in HR+/HER2Breast Cancer
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE).
-
Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Lung Cancer Patients
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low- Dose Temozolomide in Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
-
Study of nivolumab and relatilimab for untreated melanoma patients
A Randomized, Double-blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
-
Retro PT POSITIONING
Patient Positioning For Hand, Wrist, & Elbow Surgery: Stretcher Versus Or Table
-
PII/III RT THERAPY FOR PTS W/ EARLY-STAGE, P16-POS, NON-SMOKING ASSOC. OROPHARYNGEAL CANCER
A RANDOMIZED PHASE II/III TRIAL OF DE-INTENSIFIED RADIATION THERAPY FOR PATIENTS WITH EARLY-STAGE, P16-POSITIVE, NON-SMOKING ASSOCIATED OROPHARYNGEAL CANCER
-
-
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Vertex Study Number: VX18-445-113
A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Vertex Study Number: VX18-445-113
-
Blinatumomab and POMP for Acute Lymphoblastic Leukemia
A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
